- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05363605
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In phase 1, cohort 1, the potential impact of pre-dose administration of vofatamab on the dosimetry, PK, safety, and tolerability of [225Ac]-FPI-1966 and [111In]-FPI-1967 will be evaluated.
In later phase 1 cohorts, [225Ac]-FPI-1966 will be evaluated at ascending dose levels. Participants will receive [111In]-FPI-1967 during the imaging screening period to assess FGFR3 expression and to determine biodistribution and estimate radiation exposure to critical organs.
Once the recommended phase 2 dose (RP2D) or regimen is established and confirmed, three tumour-agnostic expansion cohorts may be initiated in parallel.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Trials Fusion Pharmaceutical
- Phone Number: +1 (888) 506-4215
- Email: clinicaltrials@fusionpharma.com
Study Locations
-
-
-
Melbourne, Australia
- St Vincent's Hospital
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- GC Murdoch
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Signed ICF prior to initiation of any study-specific procedures
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically and/or cytologically documented diagnosis of locally advanced, inoperable, or metastatic solid tumours
- Refractory to all standard treatments, or for whom standard treatment is not available, or tolerable, or is contraindicated, or the participant refuses standard therapy
- Measurable disease per RECIST v. 1.1
- Available tumour tissue (archival or fresh biopsy)
- Adequate bone marrow, heart, liver, and kidney function
Key Exclusion Criteria:
- Prior systemic radiopharmaceutical therapy within six months prior to the first dose of [111In]-FPI-1967
- Prior radiation therapy (RT) to bone marrow > 20 Gy
- RT within 30 days prior to the first dose of [111In]-FPI-1967
- Prior anti-cancer treatment (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents) within a certain amount of time prior to administration of the first dose of [111In]-FPI-1967
- Concurrent serious co-morbidities that could limit participants' full participation and compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1
Depending on assigned cohort, [In111]-FPI-1967/[225Ac]-FPI-1966 will be administered with or without pre-dosing with vofatamab.
|
[225Ac]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide.
In Phase 1, the dose depends on cohort assignment.
In Phase 2, the RP2D regimen will be administered.
[111In]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide.
Participants will receive [111In]-FPI-1967 Injection of 185 MBq for imaging.
Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope.
In Phase 1, the dose depends on cohort assignment.
In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
|
Experimental: Phase 2
Depending on assigned cohort, [In111]-FPI-1967/[225Ac]-FPI-1966 will be administered either with or without pre-administration of vofatamab, depending on the RP2D/regimen as determined in the phase 1 portion of the study.
|
[225Ac]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide.
In Phase 1, the dose depends on cohort assignment.
In Phase 2, the RP2D regimen will be administered.
[111In]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide.
Participants will receive [111In]-FPI-1967 Injection of 185 MBq for imaging.
Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope.
In Phase 1, the dose depends on cohort assignment.
In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase 1: Phase 1: Incidence of AEs to evaluate safety and tolerability of [225Ac]-FPI-1966, [111In]-FPI-1967, and vofatamab.
Time Frame: Approximately 2 years post final administration
|
Approximately 2 years post final administration
|
Phase 1: Maximum tolerated dose (MTD) of [225Ac]-FPI-1966
Time Frame: Approximately 42 days post administration.
|
Approximately 42 days post administration.
|
Phase 1: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest)
Time Frame: Within one week of administration
|
Within one week of administration
|
Phase 1: Effect of pre-dose administration of vofatamab on the radiation dosimetry of [111In]-FPI-1967 and [225Ac]-FPI-1966.
Time Frame: Within one week of administration
|
Within one week of administration
|
Phase 2: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Time Frame: Up to two years post final administration.
|
Up to two years post final administration.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase 1 and 2: Anti-tumour activity of [225Ac]-FPI-1966 regimen measured by response per RECIST v1.1
Time Frame: Approximately 2 years post final administration
|
Approximately 2 years post final administration
|
Phase 1 and 2: Tumour uptake of [111In]-FPI-1967 by evaluating SPECT/CT and/or planar images
Time Frame: Within one week of administration
|
Within one week of administration
|
Phase 2: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest)
Time Frame: Within one week of administration
|
Within one week of administration
|
Phase 1 and 2: Clearance for radioactivity and for the targeting antibody.
Time Frame: 28 days post final [225Ac]-FPI-1966administration
|
28 days post final [225Ac]-FPI-1966administration
|
Phase 1 and 2: Area under the curve (AUC) for radioactivity and targeting antibody
Time Frame: 28 days post final [225Ac]-FPI-1966administration.
|
28 days post final [225Ac]-FPI-1966administration.
|
Phase 1 and 2: Maximum concentration after dosing (Cmax) for radioactivity and targeting antibody.
Time Frame: 28 days post final[225Ac]-FPI-1966 administration
|
28 days post final[225Ac]-FPI-1966 administration
|
Phase 1 and 2: Half-life for radioactivity and targeting antibody.
Time Frame: 28 days post final [225Ac]-FPI-1966 administration
|
28 days post final [225Ac]-FPI-1966 administration
|
Phase 1: Changes in clearance for radioactivity and targeting antibody following pre-dose administration of vofatamab
Time Frame: 28 days post final [225Ac]-FPI-1966 administration
|
28 days post final [225Ac]-FPI-1966 administration
|
Phase 1: Changes in AUC for radioactivity and targeting antibody following pre-dose administration of vofatamab.
Time Frame: 28 days post final [225Ac]-FPI-1966 administration
|
28 days post final [225Ac]-FPI-1966 administration
|
Phase 1: Changes in Cmax for radioactivity and targeting antibody following pre-dose administration of vofatamab.
Time Frame: 28 days post final [225Ac]-FPI-1966 administration
|
28 days post final [225Ac]-FPI-1966 administration
|
Phase 1: Changes in half-life for radioactivity and targeting antibody following pre-dose administration of vofatamab
Time Frame: 28 days post final [225Ac]-FPI-1966 administration
|
28 days post final [225Ac]-FPI-1966 administration
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Julia Kazakin, MD, Fusion Pharmaceuticals Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma
- Urinary Bladder Neoplasms
- Squamous Cell Carcinoma of Head and Neck
Other Study ID Numbers
- FPI-1966-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on [225Ac]-FPI-1966
-
Fusion Pharmaceuticals Inc.RecruitingCervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)United States, Australia, Canada
-
Fusion Pharmaceuticals Inc.AstraZenecaRecruitingAdvanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal CarcinomaUnited States, Canada
-
University of PennsylvaniaNational Institutes of Health (NIH)RecruitingAlzheimer Disease | Frontotemporal Lobar Degeneration | Cognitively NormalUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownMetastatic Castration-resistant Prostate Cancer
-
Merck Sharp & Dohme LLCTerminated
-
University of MiamiNational Institute of Mental Health (NIMH)Recruiting
-
Suleyman Demirel UniversityCompletedFoot Deformities | Hallux Valgus | Pes Planus | Metatarsalgia | Feet Pes Planus (Flatfoot)Turkey
-
Fusion Pharmaceuticals Inc.RecruitingGastric Cancer | Colorectal Cancer | Ewing Sarcoma | Squamous Cell Carcinoma of Head and Neck | Pancreatic Ductal Adenocarcinoma (PDAC) | NTSR1 Expressing Solid Tumours | Neuroendocrine Differentiated (NED) Prostate CancerUnited States, Australia
-
Erasmus Medical CenterDutch Cancer SocietyRecruitingProstatic Neoplasms, Castration-ResistantNetherlands
-
Modulation Therapeutics, Inc.H. Lee Moffitt Cancer Center and Research InstituteRecruitingUveal Melanoma | MetastaticUnited States